As of 2026-01-05, the Relative Valuation of Neovacs SA (ALNEV.PA) is (535.85) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 0.01 EUR, the upside of Neovacs SA based on Relative Valuation is -6089264.0%.
The range of the Relative Valuation is (630.27) - (283.85) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 9.8x | 9.8x |
| Forward P/E multiples | 21.8x - 28.0x | 27.2x |
| Fair Price | (630.27) - (283.85) | (535.85) |
| Upside | -7162273.4% - -3225711.2% | -6089264.0% |
| Date | P/E |
| 2026-01-02 | -0.00 |
| 2025-12-31 | -0.00 |
| 2025-12-30 | -0.00 |
| 2025-12-29 | -0.00 |
| 2025-12-24 | -0.00 |
| 2025-12-23 | -0.00 |
| 2025-12-22 | -0.00 |
| 2025-12-19 | -0.00 |
| 2025-12-18 | -0.00 |
| 2025-12-17 | -0.00 |
| 2025-12-16 | -0.00 |
| 2025-12-15 | -0.00 |
| 2025-12-12 | -0.00 |
| 2025-12-11 | -0.00 |
| 2025-12-10 | -0.00 |
| 2025-12-09 | -0.00 |
| 2025-12-08 | -0.00 |
| 2025-12-05 | -0.00 |
| 2025-12-04 | -0.00 |
| 2025-12-03 | -0.00 |
| 2025-12-02 | -0.00 |
| 2025-12-01 | -0.00 |
| 2025-11-28 | -0.00 |
| 2025-11-27 | -0.00 |
| 2025-11-26 | -0.00 |
| 2025-11-25 | -0.00 |
| 2025-11-24 | -0.00 |
| 2025-11-21 | -0.00 |
| 2025-11-20 | -0.00 |
| 2025-11-19 | -0.00 |
| 2025-11-18 | -0.00 |
| 2025-11-17 | -0.00 |
| 2025-11-14 | -0.00 |
| 2025-11-13 | -0.00 |
| 2025-11-12 | -0.00 |
| 2025-11-11 | -0.00 |
| 2025-11-10 | -0.00 |
| 2025-11-07 | -0.00 |
| 2025-11-06 | -0.00 |
| 2025-11-05 | -0.00 |
| 2025-11-04 | -0.00 |
| 2025-11-03 | -0.00 |
| 2025-10-31 | -0.00 |
| 2025-10-30 | -0.00 |
| 2025-10-29 | -0.00 |
| 2025-10-28 | -0.00 |
| 2025-10-27 | -0.00 |
| 2025-10-24 | -0.00 |
| 2025-10-23 | -0.00 |
| 2025-10-22 | -0.00 |